Condition: Beta-Thalassemia · Sponsor: Genetix Biotherapeutics Inc.
The main aim of this study is to collect real-world longitudinal data on participants with β-thalassemia treated with betibeglogene autotemcel (beti-cel) in the post marketing setting. To assess the long-term safety, including the risk of newly diagnosed malignancies, after treatment with beti-cel and evaluate the long-term effectiveness of treatment with beti-cel.
This description comes directly from the study's public registry record.
bluebird bio · +1-833-999-6378 · clinicaltrials@bluebirdbio.com
Always discuss trial participation with your own doctor first.
| UCSF Benioff Children's Hospitals | Oakland, California, United States | Recruiting |
| Stanford University | Palo Alto, California, United States | Recruiting |
| University of Minnesota | Minneapolis, Minnesota, United States | Recruiting |
| Cohen Children's Medical Center | New Hyde Park, New York, United States | Recruiting |
| Children's Hospital of Philadelphia | Philadelphia, Pennsylvania, United States | Recruiting |
| Texas Children's Hospital | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06271512